Exdensur (depemokimab) approved by US FDA for the treatment of severe asthma

GSK’s Exdensur (depemokimab) has been approved by the US FDA as an add-on maintenance therapy for severe eosinophilic asthma (ages 12+), after SWIFT‑1 and SWIFT‑2 phase III trials showed 58% and 48% reductions in annualised exacerbation rates versus placebo and a pooled 72% reduction in exacerbations requiring hospitalisation/ED visits; the drug was generally well tolerated. As the first ultra‑long‑acting biologic designed for twice‑yearly dosing, Exdensur addresses a key barrier to biologic uptake (only ~20% of eligible US patients currently receive biologics) and could boost adherence and market penetration while reducing health‑system burden. With MHRA approval, a positive CHMP opinion and ongoing submissions in China and Japan, plus additional phase III programs in related type‑2 inflammatory diseases, the approval materially strengthens GSK’s respiratory franchise and presents notable commercial upside if adoption scales.

Analysis

GSK announced US FDA approval of Exdensur (depemokimab-ulaa) as an add-on maintenance therapy for severe asthma with an eosinophilic phenotype in patients aged 12 and older. Approval was based on SWIFT‑1 and SWIFT‑2 phase III trials (382 and 380 participants) that reported 58% and 48% reductions in annualised exacerbation rates versus placebo (SWIFT‑1 rate ratio 0.42, 95% CI 0.30–0.59, p<0.001; SWIFT‑2 rate ratio 0.52, 95% CI 0.36–0.73, p<0.001) with absolute AERs of 0.46 vs 1.11 and 0.56 vs 1.08 respectively.

A pre‑specified pooled analysis showed a 72% reduction in exacerbations requiring hospitalisation/ED visits (rate ratio 0.28, 95% CI 0.13–0.61, nominal p=0.002; AER 0.02 vs 0.09), and depemokimab was reported as well tolerated with adverse event rates similar to placebo. Exdensur is the first ultra‑long‑acting biologic designed for twice‑yearly dosing, a differentiator that GSK and physician surveys suggest could improve adherence given only ~20% of eligible US patients currently receive biologics and an estimated 2 million Americans have severe asthma with half experiencing frequent exacerbations.

Regulatory momentum includes UK MHRA authorisation, a positive CHMP opinion and pending submissions in China and Japan, with an EU decision expected in Q1 2026; SWIFT results were published in NEJM and presented at ERS, supporting credibility. GSK is also running multiple phase III programmes in CRSwNP, EGPA, HES and COPD, meaning commercial upside hinges on both launch execution and pipeline readouts.

Key risks include uncertain payer coverage, real‑world uptake from a historically under‑penetrated biologics market, pricing dynamics and the need to confirm long‑term safety and durability outside trial settings, consistent with GSK's own forward‑looking cautions.

Key Decisions for Investors

• Consider a modest overweight in GSK to reflect the incremental franchise upside from Exdensur's differentiated twice‑yearly dosing, but scale the position gradually around commercial launch data
• Monitor launch KPIs closely—initial US prescription volumes, payer reimbursement decisions, patient uptake versus existing biologics, and the EU decision in Q1 2026 as primary near‑term catalysts
• Maintain downside protection until real‑world safety, durability and pricing/reimbursement are confirmed and watch upcoming phase III readouts in additional indications that could materially expand addressable markets